Effect of late culprit coronary artery revascularization on prognosis of patients with ST-elevation myocardial infarction

Aim. To evaluate the effect of culprit coronary artery revascularization after 48 hours from the symptoms’ onset on the prognosis of patients with ST-elevation myocardial infarction (STEMI).

Material and methods. Of the 1172 patients admitted to City Clinical Hospital № 13 in 2018 due to STEMI, 43 patients (4%) were included in the retrospective study. There were following inclusion criteria: hospitalization after 48 hours from the symptoms’ onset, no clinical signs of myocardial ischemia, and complete coronary artery occlusion according to angiography. The mean age of the subjects was 61,3±10,6 years, 34 (79%) men and 9 (21%) women. The subjects were divided into two groups: group 1 (n=22) — management with percutaneous coronary intervention (PCI), group 2 (n=21) — management with medications. The groups differ only in the severity of coronary atherosclerosis according to SYNTAX score: group 1 — 14,0 [11.0; 19.5], group 2 — 26,0 [16,5; 31,0] (p=0,009). At the end of inpatient treatment, patients underwent echocardiography. Death and myocardial infarction were monitored during hospitalization and for 12 months after discharge.

Results. During hospitalization, 2 patients died (4,7%; one in each group, p=1,00). No recurrent MI were reported. The left ventricular ejection fraction in the PCI group was 50 [46; 54] %, in the group with drug therapy — 43 [38; 50] % (p=0,01). Out of 43 included patients, long-term outcomes were followed up in 32 (74%). Among them, 1 (5,8%) patient died in group 1, 6 (33,3%) patients — in group 2 (p=0,04). In total, death or recurrent MI in the first group was observed in 2 (12%) patients, in the second group — in 5 (33%) patients (p=0,14).

Conclusion. Revascularization of a fully occluded culprit coronary artery in stable patients with STEMI after 48 hours of symptoms’ onset is associated with a higher inhospital left ventricular ejection fraction and a decrease in 12-month mortality.

1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2017;39(2):119-77. doi:10.1093/eurheartj/ehx393.

2. Erlikh AD. The First Moscow Acute Coronary Syndrome Registry: the results of six-month follow-up. Emergency Cardiology. 2014;2:3-9. (In Russ.)

3. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. doi:10.1093/eurheartj/ehy394.

4. Schomig A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005;293(23):2865-72. doi:10.1001/jama.293.23.2865.

5. Hochman JS, Lamas GA, Buller CE, et al. Coronary Intervention for Persistent Occlusion after Myocardial Infarction. N Engl J Med. 2006;355(23):2395-407. doi:10.1056/nejmoa066139.

6. Ioannidis JP, Katritsis DG. Percutaneous coronary intervention for late reperfusion after myocardial infarction in stable patients. Am Heart J. 2007;154(6):1065-71. doi:10.1016/j.ahj.2007.07.049.

7. Timmis A, Townsend N, Gale C, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2017. Eur Heart J. 2018;39(7):508-79. doi:10.1093/eurheartj/ehx628.

8. Erlikh AD, Gratsiansky NA. Registry of Acute Coronary Syndromes “RECORD-3”. Characteristics of Patients and Treatment During. Kardiologiia. 2016;5(4):16-24. (In Russ.) doi:10.18565/cardio.2016.4.16-24.

9. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237-69. doi:10.1093/eurheartj/ehy462.

10. Hochman JS, Lamas GA, Knatterud GL, et al. Design and methodology of the Occluded Artery Trial (OAT). Am Heart J. 2005;150(4):627-42. doi:10.1016/j.ahj.2005.07.002.

11. White HD, Reynolds HR, Carvalho AC, et al. Reinfarction Following PCI or Medical Management using the Universal Definition in Patients With Total Occlusion After Myocardial Infarction: Results from Long Term Follow up of the OAT Cohort. Am Heart J. 2012;163(4):563-71. doi:10.1016/j.ahj.2012.01.016.

12. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213-60. doi:10.1093/eurheartj/ehx419.

13. Dzavik V, Buller CE, Lamas GA, et al. Randomized Trial of Percutaneous Coronary Intervention for Subacute Infarct-Related Coronary Artery Occlusion to Achieve Long-Term Patency and Improve Ventricular Function: The Total Occlusion Study of Canada (TOSCA)2 Trial. Circulation. 2006;114(23):2449-57. doi:10.1161/circulationaha.106.669432.

14. Menon V, Pearte CA, Buller CE, et al. Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial. Eur Heart J. 2009;30(2):183-91. doi:10.1093/eurheartj/ehn486.

15. Ndrepepa G, Kastrati A, Mehilli J, et al. Mechanical Reperfusion and Long-term Mortality in Patients With Acute Myocardial Infarction Presenting 12 to 48 Hours From Onset of Symptoms. JAMA. 2009;301(5):487-8. doi:10.1001/jama.2009.32.